DXCM DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages DexCom, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - DXCM

Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. who incurred losses exceeding $100,000 during the specified class period to secure legal counsel before the December 29, 2025 deadline for lead plaintiff applications [1]. Group 1: Class Action Details - Investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information via the provided link or contact the firm directly for further details [3][6]. - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in recovering significant settlements for investors [4]. - The firm has been recognized for its success in securities class action settlements, including a notable recovery of over $438 million for investors in 2019 [4]. - Investors are advised that until a class is certified, they are not represented unless they retain counsel, and they have the option to remain absent from the class [7].